A Study of PM1009 (Anti-TIGIT/PVRIG) in Patients With Advanced Tumours

Inclusion Criteria: * Patients participate in the study voluntarily and sign informed consent； * Male or female, aged 18 to 75 years (including boundary value); * Subjects with advanced tumor confirmed by histology or cytology fail to receive standard treatment, or there is no standard treatment scheme, or standard treatment is not applicable at this stage; * Having adequate organ function； * ECOG score is 0-1； * Expected survival ≥ 12 weeks； * There is at least one assessable tumor focus. Exclusion Criteria: * History of severe allergic; * Those who have received anti-TIGIT or anti-PVRIG therapy in the past; * Patients who have grade ≥3 immune-mediated adverse event that associated with a prior immunotherapy; * Adverse reactions to previous antitumor therapy have not recovered to NCI-CTCAE V5.0 rating ≤ 1; * Current definite interstitial lung disease or non-infectious pneumonitis, except for local radiotherapy; * Patients ever received the following treatments or drugs prior to the study treatment: 1. Major organ surgery within 28 days prior to initiation of trial treatment; 2. Received live attenuated vaccine within 28 days prior to the study treatment; 3. Received antitumor therapy within 4 weeks prior to the study treatment; 4. Received systemic glucocorticoid within 14 days prior to the study treatment; * Active infection was present within 14 days before starting study treatment; * Those with known uncontrolled parenchymal or leptomeningeal metastases; * Patients with active autoimmune disease or a history of autoimmune disease with potential for relapse; * Patients with other active malignancies within 5 years prior to initiation of study treatment, except for locally treatable and cured malignancies; * History of severe cardiovascular and cerebrovascular diseases; * Patients with uncontrolled tumor-related pain; * Current presence of uncontrolled pleural, pericardial, and peritoneal effusions; * History of allogeneic hematopoietic stem cell transplantation or allogeneic organ transplantation; * History of alcohol, psychotropic substance or drug abuse; * History of psychiatric disorders or poor compliance; * History of immunodeficiency, including a positive HIV antibody test; * Patients with active syphilis infection; * Patients with active hepatitis B or C; * Pregnant or lactating women; * Other conditions considered unsuitable for this study by investigator.